From: Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study
Placebo | Masitinib | ||||
---|---|---|---|---|---|
All (n = 6) | All (n = 24) | PPMS (n = 9) | SPMS (n = 15) | ||
Relative change in MSFC score * | Mean ± SD | -60% ± 190 | 103% ± 189 | 134% ± 268 | 84% ± 130 |
Relative change in T25FW | Mean ± SD | 26% ± 55 | 5% ± 26 | 13% ± 17 | -1% ± 29 |
Relative change in 9-HPT | Mean ± SD | 0% ± 13 | -7% ± 9 | -5% ± 7 | -8% ± 10 |
Relative change in PASAT-3” | Mean ± SD | 24% ± 30 | 41% ± 111 | 19% ± 66 | 55% ± 131 |
Absolute change in EDSS score | Mean ± SD | 0.3 ± 1.0 | 0.0 ± 0.5 | 0.1 ± 0.4 | 0.0 ± 0.5 |